



Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile

Guest Editor:

Prof. Dr. Maria Contel

Department of Chemistry,
Brooklyn College and The
Graduate Center, The City
University of New York, Brooklyn,
NY 11210, USA

Deadline for manuscript
submissions:

closed (31 October 2018)

Message from the Guest Editor

Dear Colleagues,

For the past forty years, metal-based drugs have been widely used for the treatment of cancer. Cisplatin and follow-up drugs carboplatin and oxaliplatin have been the gold standard for metallodrugs in clinical settings as antineoplastic agents. While effective, these drugs have faced a number of clinical challenges resulting from their limited spectrum of activity, high toxicity leading to significant side effects, resistance, poor water solubility, low bioavailability and short circulating time. In parallel to the synthesis of coordination and organometallic compounds comprising many different metals and unconventional platinum-based derivatives, researchers are focused in optimizing mechanistic and pharmacological features of promising drug candidates. This Special Issue aims to highlight the latest advances in anticancer metallodrugs with a focus on unconventional anticancer agents, as well as novel activation, targeting and delivery strategies aimed at improving their pharmacological profile.

Prof. Dr. Maria Contel
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Duncan H. Gregory

School of Chemistry, University of
Glasgow, University Avenue,
Glasgow G12 8QQ, UK

Message from the Editor-in-Chief

Inorganic chemistry remains a lynchpin of modern chemistry, not only embracing the function and reactivity of combinations of most elements of the periodic table, but also providing a footing for studies of materials, catalysts, drugs, fuels and industrial chemicals. Arguably, the role and reach of inorganics in society have never been as great as today. Adventurous research at the heart and at the extremes of inorganic chemistry is vital to further advances and *Inorganics* offers authors the opportunity to publish exciting new research in an open access format.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Chemistry, Inorganic & Nuclear*) / CiteScore - Q2 (*Inorganic Chemistry*)

Contact Us

Inorganics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/inorganics
inorganics@mdpi.com
[X@inorganics_MDPI](https://twitter.com/inorganics_MDPI)